Cleared Special

K203136 - Diazyme PLAC® Test for Lp-PLA2 Activity (FDA 510(k) Clearance)

Aug 2021
Decision
290d
Days
Class 2
Risk

K203136 is an FDA 510(k) clearance for the Diazyme PLAC® Test for Lp-PLA2 Activity. This device is classified as a Test, System, Immunoassay, Lipoprotein-associated Phospholipase A2 (Class II - Special Controls, product code NOE).

Submitted by Diazyme Laboratories, Inc. (Poway, US). The FDA issued a Cleared decision on August 6, 2021, 290 days after receiving the submission on October 20, 2020.

This device falls under the Chemistry FDA review panel. Regulated under 21 CFR 866.5600. The Lipoprotein-associated Phospholipase A2, Immunoassay, System, Test, Is Intended To Measure Lipoprotein-associated Phospholipase A2 In Human Plasma In Conjunction With Clinical Evaluation And Other Patient Risk Factors Including Biochemical Analyses As An Aid In Predicting Risk For Coronary Heat Disease. This Device Differs From The Classification Regulation In That It Is A Different Analyte, Thus A New Marker For Predicting Risk Of Coronary Heart Disease. This Device Is Measuring An Enzyme That Is Produced By Macrophages Where As The Regulation Is For The Measurement Of A Lipoprotein..

Submission Details

510(k) Number K203136 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 20, 2020
Decision Date August 06, 2021
Days to Decision 290 days
Submission Type Special
Review Panel Chemistry (CH)
Summary Statement

Device Classification

Product Code NOE — Test, System, Immunoassay, Lipoprotein-associated Phospholipase A2
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.5600
Definition The Lipoprotein-associated Phospholipase A2, Immunoassay, System, Test, Is Intended To Measure Lipoprotein-associated Phospholipase A2 In Human Plasma In Conjunction With Clinical Evaluation And Other Patient Risk Factors Including Biochemical Analyses As An Aid In Predicting Risk For Coronary Heat Disease. This Device Differs From The Classification Regulation In That It Is A Different Analyte, Thus A New Marker For Predicting Risk Of Coronary Heart Disease. This Device Is Measuring An Enzyme That Is Produced By Macrophages Where As The Regulation Is For The Measurement Of A Lipoprotein.